Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study
Authors
Linda-Ali Cruz
Robert J. Fox (ORCID: https://orcid.org/0000-0002-4263-3717)
Yang Mao‐Draayer (ORCID: https://orcid.org/0000-0001-6248-3480)
Stanley Cohan (ORCID: https://orcid.org/0000-0002-9568-346X)
Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study
Linda-Ali Cruz, Robert J. Fox, Yang Mao‐Draayer, Stanley Cohan et al.
Citations
1 citations
Journal
Multiple Sclerosis Journal
Topics
Multiple Sclerosis Research Studies
Field-Weighted Citation Impact (FWCI)
1.47
article
Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study
Linda-Ali Cruz, Robert J. Fox, Yang Mao‐Draayer, Stanley Cohan, Bianca Weinstock‐Guttman, Gina Mavrikis Cox, Amit Bar‐Or, Sophie Arnould
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Multiple Sclerosis JournalVol. 31(6)
Institutions
Providence St. Vincent Medical Center (US), Novartis (Switzerland) (CH), Cleveland Clinic (US), Oklahoma Medical Research Foundation (US), Novartis (United States) (US), Jacobs Institute (US), University of Pennsylvania (US)